Related Experiment Videos
Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it?
1Department of Radiotherapy and Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK.
European Journal of Cancer (Oxford, England : 1990)
|October 1, 1996
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy.
Clinical oncology (Royal College of Radiologists (Great Britain))·2022
How Low Can You Go? The Radiobiology of Hypofractionation.
Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.
Clinical oncology (Royal College of Radiologists (Great Britain))·2021
The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.
Clinical oncology (Royal College of Radiologists (Great Britain))·2016
Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
Clinical oncology (Royal College of Radiologists (Great Britain))·2016
Multileaf collimation cardiac shielding in breast radiotherapy: Cardiac doses are reduced, but at what cost?
Clinical oncology (Royal College of Radiologists (Great Britain))·2013
Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.
European journal of cancer (Oxford, England : 1990)·2026
Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma.
European journal of cancer (Oxford, England : 1990)·2026
Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.
European journal of cancer (Oxford, England : 1990)·2026
Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.
European journal of cancer (Oxford, England : 1990)·2026
Geneo study: Comprehensive genomic profiling versus limited local reimbursed NGS panels within the belgian Precision initiative.
European journal of cancer (Oxford, England : 1990)·2026
Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial.
European journal of cancer (Oxford, England : 1990)·2026